Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<div>Abstract<p>The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO + VEN) ± azacitidine (AZA; IVO + VEN + AZA) were evaluated in four cohorts of patients with <i>IDH1</i>-mutated myeloid malignancies (<i>n</i> = 31). Most (91%) adverse events were grade 1 or 2. The maximal tolerated dose was not reached. Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)–evaluable patients (<i>N</i> = 16), 63% attained MRD-­negative remissions; <i>IDH1</i> mutation clearance occurred in 64% of patients receiving ≥5 treatment cycles (<i>N</i> = 14). Median event-free survival and overall survival were 36 [94% CI, 23–not reached (NR)] and 42 (95% CI, 42-NR) months. Patients with signaling gene mutations appeared to particularly benefit from the triplet regimen. Longitudinal single-cell proteogenomic analyses linked cooccurring mutations, antiapoptotic protein expression, and cell maturation to therapeutic sensitivity of <i>IDH1</i>-mutated clones. No IDH isoform switching or second-site <i>IDH1</i> mutations were observed, indicating combination therapy may overcome established resistance pathways to single-agent IVO.</p>Significance:<p>IVO + VEN + AZA is safe and active in patients with <i>IDH1</i>-mutated myeloid malignancies. Combination therapy appears to overcome resistance mechanisms observed with single-agent IDH-inhibitor use, with high MRD-negative remission rates. Single-cell DNA ± protein and time-of-flight mass-cytometry analysis revealed complex resistance mechanisms at relapse, highlighting key pathways for future therapeutic intervention.</p><p><i><a href="" target="_blank">This article is highlighted in the In This Issue feature, p. 247</a></i></p></div>

Original publication





Publication Date